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Vaccination with live attenuated pathogenic viruses has a long tradition, although few people are aware of this. Already in the fifth century AD, variolation, the vaccination against smallpox virus with material from pustules of infected people, was practiced in China and later in India as well as in Japan and Europe (Mazumdar [@CR155_5]). The material was applied intradermally or nasally. At a pending smallpox epidemic, even the grandchildren of George I, king of England, were variolated after rudimentary safety and efficacy trials using death-sentenced prisoners and orphans for testing. Although highly protective, variolation never reached general compliance in the Western world partly because a certain death toll had to be paid using this method. It was not before the groundbreaking experiment by Edward Jenner in 1796 that vaccination was generally accepted. Jenner prevented smallpox disease in a 13-year-old boy by preinoculation with cowpox virus and established convincingly the principle of immunization by the use of active agents, at this time without knowledge about the nature of the immunogen or the immune system. Following the discovery of pathogenic bacteria, Louis Pasteur pioneered the development of several vaccines. In 1879, he generated the first live attenuated bacterial vaccine by extended culture of fowl cholera bacteria, which could be applied to chicken without causing disease but preventing them from infection with a virulent strain (Pasteur [@CR178_5]). This discovery marks the starting point for the development of live attenuated vaccines (LAV). Within the next 20 years at the end of the nineteenth century, a number of further vaccines quickly appeared, for example, anthrax and rabies vaccines developed by Pasteur or human vaccines against typhoid fever, cholera, and plague (Makela [@CR149_5]). Since then, many LAV for human and animal use were developed until today, including live attenuated bacteria, fungi, parasites, and viruses. Such vaccines continue to have a tremendous impact in the prevention of infectious diseases despite a number of other vaccine classes have been introduced over time. This reflects unique characteristics of LAV, which are unmet by other vaccines thus far with respect to the induction of protective immune responses against specific pathogens (Table [5.1](#Tab1_5){ref-type="table"}).Table 5.1Pros and cons of current LAVProsConsSimulation of natural infection courseRisk of reversion to virulenceInduction of cellular and antibody responsesRisk for immunocompromised individualsInduction of mucosal and systemic immunityRisk of environmental release and spreadingMucosal administration routesReactogenicityHigh efficacy, single or few doses requiredHigh costs during developmentLong-lasting immunityShort shelf-lifeNo adjuvant requiredRegulatory hurdlesNo preservative requiredPublic resistance to genetically modified LAVLow production costEasy transport and storage

One of the hallmarks of LAV is that they efficiently target immune inductive sites during their limited infection cycle in the host. In contrast to the majority of other currently used vaccines, which preferentially induce antibody-mediated immune protection, LAV are capable of stimulating cellular immunity as well. However, potential risks such as virulence reversion or side effects particularly in immunocompromised individuals led to the replacement of some of the successful LAV in the past and raised continuously standards for approval of new live vaccines especially for human use (Table [5.1](#Tab1_5){ref-type="table"}). For animals, benefit risk assessments of LAV often have a more positive outcome. The comparatively small number of approved human LAV is opposed to a relatively large number of veterinary LAV against a whole array of pathogens today.

The advent of recombinant DNA technology opened up the possibility of targeted modification of microbes. This paved the way for rational attenuation of LAV, rendering them nonpathogenic even in the absence of a functional host immune system and inert to changes in diet, commensal flora, or other individual traits. In addition, the use of LAV as delivery systems for foreign antigens derived from other pathogens or therapeutic molecules is now possible. Meanwhile, a considerable number of such recombinant LAV advanced into clinical testing or even have obtained marketing authorization. Notably, most approved recombinant LAV thus far are veterinary vaccines (Meeusen et al. [@CR157_5]). However, the rapidly expanding knowledge about host--microbe interactions and recent technological advances, such as genome sequencing, global expression analysis techniques, as well as high end gene synthesis, will open up completely new ways to rationally design LAV as such or for recombinant vaccine delivery. Eventually, it will be possible to develop a new generation of LAV tailored for specific applications with an excellent safety and efficacy profile. Thus, harnessing the potential of LAV to induce all arms of the immune system, these vaccines probably will provide new options in the fight against major threads to human and animal health. Depending on the vector system of choice, "vaccine cargo" of different nature, size, and amount can be delivered. Whereas viral vaccine vectors in most cases will carry the genetic information of foreign antigens in order to mediate their expression in the host cells, other microbial vector systems offer more flexibility with respect to delivery and release of foreign antigens. Such delivery systems have been designed either to directly produce antigenic peptides or to deliver antigen-encoding nucleic acids to host cells.

Bacterial LAV and Their Use for Vaccine Delivery {#Sec2_5}
================================================

Bacterial LAV in Use Today and Novel Attenuation Strategies {#Sec3_5}
-----------------------------------------------------------

The majority of pathogenic bacteria either colonize or transit mucosal compartments during infection. In order to prevent bacterial infection and spreading of disease, the induction of mucosal immune responses is of particular importance. Bacterial LAV are regarded as prototype mucosal vaccines capable to induce mucosal as well as systemic immune responses (Dietrich et al. [@CR55_5]; Kochi et al. [@CR114_5]). In addition, mucosal vaccines often simplify administration, thereby enhancing safety and reducing costs of vaccination. Originally, most bacterial LAV were empirically derived from pathogenic isolates. Undirected methods such as passaging or chemical or physical mutagenesis were employed in order to reduce virulence of such strains yet retain their ability to transiently colonize host tissues and induce protective immunity. Such methods were stepwise replaced since the 1980s by directed mutagenesis. Currently, only three bacterial LAV are licensed for human use, namely, Bacillus Calmette-Guerin (BCG), *Salmonella enterica* serovar Typhi (*S. typhi*) strain Ty21a, and *Vibrio cholerae* (*V. cholerae*) strain CVD 103-HgR. In contrast, a wide range of bacterial LAV are utilized in veterinary medicine.

In case of the parenteral tuberculosis (TB) vaccine, BCG was passaged in culture medium for more than a decade and gave rise to the attenuated variant of the original *Mycobacterium bovis* isolate in 1919 (Calmette et al. [@CR25_5]). Since then, BCG has been administered to about four billion people being therefore the most widely used bacterial LAV for human use thus far. However, BCG alone is unable to prevent pulmonary TB in adults. Only newborns can be temporarily protected this way, except HIV-infected babies (Mansoor et al. [@CR150_5]). In order to prevent a resurgence of TB due to reasons such as increasing occurrence of multidrug-resistant *Mycobacterium tuberculosis* strains or the prevalence of HIV, new vaccines are urgently needed. Improved recombinant BCG alone or as part of prime--boost approaches constitutes an important route of TB vaccine development (Kaufmann et al. [@CR106_5]). As a replacement of BCG, also *M. tuberculosis*-derived attenuated variants are tested (Gonzalo-Asensio et al. [@CR79_5]). As veterinary vaccine, BCG has been used successfully against bovine TB (Buddle et al. [@CR22_5]).

The human LAV against typhoid fever *S. typhi* Ty21a and cholera *V. cholerae* CVD 103-HgR are orally administered. The vaccine strain *S. typhi* Ty21a has been obtained in the 1970s by chemical mutagenesis with nitrosoguanidine (Germanier and Fürer [@CR73_5]). Colonies were screened for their sensitivity to galactose due to a lack of the enzyme uridine diphosphate galactose epimerase (*galE*). The reasoning was that such bacteria would then be deficient of the polysaccharide coat and therefore rendered vulnerable to the immune system. Unintentionally, a number of additional attenuating mutations were introduced this way (Germanier and Fürer [@CR74_5]).

About 10 years later, the cholera vaccine strain *V. cholerae* CVD 103-HgR was more rationally derived from the pathogenic isolate by genetic engineering (Levine and Kaper [@CR128_5]). Gene *ctxA* encoding the toxic A subunit of the cholera toxin was deleted causing sufficient strain attenuation while leaving the expression of the immunogenic B subunit unaffected. Furthermore, gene *hlyA* encoding hemolysin was disrupted by integration of a mercury resistance gene, which allows discrimination from wild-type strains.

In veterinary medicine, since decades, many LAV against bacterial diseases are in use, which were established in most cases by undirected mutagenesis. Most prominent examples are vaccines against salmonellosis for poultry, swine, and cattle. Various serovars of *Salmonella enterica* are causative agents of either enteritis or septicemia in animals. In turn, contaminated animal-derived food products are the main sources for human *Salmonella* infections (Barrow [@CR13_5]). Attenuated *Salmonella* vaccine strains established by chemical mutagenesis have been introduced into veterinary practice in the 1970s and are often in use until today (Linde et al. [@CR131_5]; Meyer et al. [@CR162_5]). Directed attenuation by genetic engineering became feasible in the 1980s. A number of suitable gene targets were identified, belonging mainly to metabolic pathways, regulatory systems, or virulence determinants. Interference with synthesis of aromatic amino acids by deletion of gene *aroA* (encoding 5-enolpyruvyl shikimate-3-phosphate synthase) proved to be an excellent strategy for safe attenuation while retaining immunogenicity of a *S. typhimurium* strain (Hoiseth and Stocker [@CR95_5]). This concept was subsequently transferred for attenuation to a number of other bacteria, such as *Aeromonas salmonicida* (Vaughan et al. [@CR217_5]), *Yersinia enterocolitica* (Bowe et al. [@CR19_5]), *Pasteurella multocida* (Homchampa et al. [@CR96_5]), *Escherichia coli* (Fan et al. [@CR60_5]), and *Streptococcus equi* (Jacobs et al. [@CR100_5]), of which several strains were successfully commercialized as LAV for animal use. As a strategy to reduce the likelihood of virulence reversion, e.g., due to unwanted acquisition of complementing DNA sequences, attenuation of multiple genes was proposed. Mutations of genes *aroA* and *aroD*, both part of the same metabolic pathway, were introduced into vaccine strains of *S. typhi* (Chatfield et al. [@CR31_5]) and *Shigella flexneri* (Verma and Lindberg [@CR218_5]).

A prerequisite for the use of animal vaccines is often the ability to *d*ifferentiate *i*nfected from *v*accinated *a*nimals (DIVA concept) (van Oirschot [@CR216_5]). This can be achieved by deletion of an immunogenic antigen such that vaccinated animals are seronegative for it but not for other protective vaccine antigens. In the case of *Actinobacillus pleuropneumoniae*, the causative agent of porcine pleuropneumonia, sequential deletion of six genes gave rise to an appropriate attenuated candidate vaccine strain, which also complies to the DIVA concept (Maas et al. [@CR147_5]).

However, the removal of virulence determinants often gives rise to strains, which fail to transiently colonize immune inductive sites and therefore do not induce potent immune responses. In accordance, the so-called strategy of regulated delayed attenuation was established recently in order to circumvent this problem (Curtiss III et al. [@CR46_5]). Here, the vaccine strain is designed in a way that the invasive phenotype of the strain is retained during the initial phase of vaccination until immune inductive sites have been colonized. Subsequently, due to the lack of a particular substrate in vivo, the invasive phenotype of bacteria fades before acute disease is elicited. Proof of concept was established with mutant strains lacking either genes *galE* or *pmi* (phosphomannose isomerase) (Curtiss III et al. [@CR47_5]). Such mutants are attenuated due to the lack of functional lipopolysaccharide (LPS). However, when grown in the presence of either galactose or mannose, respectively, these mutants synthesize LPS and are able to colonize host tissue upon oral administration. Since both sugars are not present in vivo, LPS synthesis is subsequently abrogated and bacteria rendered vulnerable to host defenses.

Finally, after successful establishment and clinical testing of a bacterial LAV, careful risk assessment is necessary prior to vaccine registration (Frey [@CR64_5]). Despite safety concerns for the approval of genetically modified LAV at present, rationally engineered strains will probably gain acceptance in the future due to the high degree of molecular definition in addition to their superior performance.

Recombinant Bacterial LAV for Vaccine Delivery {#Sec4_5}
----------------------------------------------

Bacterial LAV have a proven track record of efficacy in human and veterinary medicine. In addition, the understanding of LAV interaction with the host immune system has greatly advanced (Kaufmann [@CR105_5]). This is an excellent basis for the development of a next generation of bacterial LAV. Existing vaccines will eventually be replaced by refined strains, in which, in addition to defined attenuation, a number of other features are rationally designed like modulated expression of immunogenic components (Fig. [5.1](#Fig1_5){ref-type="fig"}). Furthermore, recombinant DNA technology provides the possibility to program such strains at the same time as delivery system for foreign antigens, nucleic acid-based vaccines, or therapeutic molecules (Fig. [5.1](#Fig1_5){ref-type="fig"}). By now, a wide range of bacteria are explored for these purposes. In this case, distinct properties of bacterial species can be harnessed or diverted depending on the specific needs for the spectrum of medical applications (Fig. [5.2](#Fig2_5){ref-type="fig"}). Nonpathogenic bacteria such as food-derived or commensal lactic acid bacteria are attractive for the delivery of vaccines and therapeutics especially via the mucosa because they are considered of being generally safe (Wells and Mercenier [@CR224_5]). In contrast to invasive attenuated bacteria, they do not actively enter and replicate inside host cells. Therefore, release of heterologous antigens from such bacteria occurs primarily in the extracellular space (Fig. [5.2](#Fig2_5){ref-type="fig"}a). In accordance, they mainly stimulate induction of antibody responses in several vaccination models. However, extracellular LAV can also be engineered to directly inject heterologous antigens into the host cell cytosol in order to induce cytotoxic T-cell responses (Fig. [5.2](#Fig2_5){ref-type="fig"}a). This was first demonstrated by employing an extracellular *Yersinia pseudotuberculosis* carrier strain mediating the cytosolic delivery of listeriolysin O (LLO), a protective antigen of *Listeria monocytogenes* (*L. monocytogenes*), via its type III secretion apparatus (Russmann et al. [@CR188_5]). More often, recombinant LAV have been derived from bacteria capable of invading host cells, such as *Salmonella* spp., *L. monocytogenes*, or *Shigella flexneri* (Curtiss III [@CR44_5]; Kotton and Hohmann [@CR117_5]). In case of *Salmonella*, subsequent to cellular invasion, bacteria reside naturally inside a phagosome. They subvert this compartment into a protected niche for proliferation. Presentation of heterologous antigens expressed by attenuated *Salmonella* that undergo disintegration in this compartment is therefore restricted mainly to the MHC-II pathway leading to CD4 T-cell activation (Fig. [5.2](#Fig2_5){ref-type="fig"}b). In contrast, *L. monocytogenes* or *Shigella flexneri* escape the vacuolar compartment soon after cellular uptake and replicate inside the cytosol. Thus, upon carrier disintegration, vaccine cargo can be directly released into the cytoplasm (Fig. [5.2](#Fig2_5){ref-type="fig"}c). This allows presentation of heterologous antigens via MHC-I molecules to CD8 T-cells. However, the great advances in understanding the molecular mechanisms, which lead to a particular bacterial function such as host cell invasion, intracellular residence, etc., will allow more and more to interchange the underlying molecular systems between bacterial species in order to tailor bacterial LAV precisely for specific applications.Fig. 5.1*Next-generation bacterial LAV for vaccine delivery*. The development of a new bacterial LAV for the delivery of a specific vaccine is a complex and individual process for each application. First, a suitable bacterial carrier strain has to be selected and to be attenuated in a defined manner (*red symbols*). In order to potentiate vector-directed immune responses (if intended) or to provide optimal adjuvant activity components of the strain can be modulated (*blue symbols*). Examples for modulation could be overexpression of immunogenic surface proteins or the removal of anti-apoptotic genes from the carrier strain in order to strengthen cross-priming. The synthesis and delivery of heterologous protein and/or nucleic acids requires precise programming of the vaccine strain (*green symbols*). Expression cassettes are either located on plasmids or integrated into the chromosome. Expression determinants and coding sequences can be optimized. Finally, release and transfer of vaccine components from bacteria to the immune cells can either be achieved by secretion or bacterial disintegration Fig. 5.2*Delivery of heterologous antigens or nucleic acids by bacterial LAV*. (**a**) Heterologous antigen delivery by extracellular bacteria. Antigens can either be released outside the host cell or delivered into the host cell cytoplasm, e.g., by a type III secretion system. (**b**) Delivery of heterologous antigens from bacteria which are restricted to an intracellular vacuole, e.g., *Salmonella*. Antigens can either be targeted to the vacuole or to the cytosol. (**c**) Bacteria capable of vacuolar escape can deliver heterologous antigen directly to the cytoplasm of the host cell upon degradation or by secretion

In the present chapter, we will focus especially on *Salmonella* vaccine vectors in order to exemplify major improvement strategies for the development of bacterial LAV in general. *Salmonella* LAV constitute promising vectors for heterologous antigens because after oral administration, they are able to invade and colonize mucosal and systemic immune inductive compartments at the same time. Thus, long-lasting humoral and cellular immune responses have been induced against a wide spectrum of antigens delivered by *Salmonella* LAV (Galen et al. [@CR70_5]; Kwon et al. [@CR121_5]; Moreno et al. [@CR164_5]). In addition to the selection of a suitable vector strain which meets the balance between immunogenicity and safety (as discussed before), the strategy of heterologous antigen synthesis and delivery has to be carefully considered for each antigen and the anticipated immune response (Galen and Levine [@CR68_5]; Kotton and Hohmann [@CR117_5]). Definition and implementation of such a strategy can be a very challenging and complex process.

### Level and Timing of Antigen Expression {#Sec5_5}

For the induction of strong antibody responses, high amounts of antigen are required in most cases, whereas for cellular responses, moderate antigen delivery may suffice. Therefore, strong constitutive promoters were used initially for the expression of heterologous antigens by bacterial LAV (Brown et al. [@CR21_5]). However, even when achieved at all, such high-level expression of antigen often constitutes a serious burden for the vaccine strain, which reduces its ability of tissue colonization and to induce immune responses. As a solution to this problem, the use of in vivo inducible (IVI) promoters was proposed which are derived from genes that become activated under conditions encountered at certain stages of the colonization course. At first, the nitrite reductase promoter (P~*nirB*~) of *E. coli* was employed which is induced by intestinal hypoxia (Chatfield et al. [@CR30_5]). Subsequently, a number of additional IVI promoters were tested for the expression of heterologous antigens (Hohmann et al. [@CR94_5]; Stratford et al. [@CR205_5]; Valdivia and Falkow [@CR214_5]). Each individual promoter differs in the timing and level of antigen expression and consequently influences the antigen-specific immune induction (Bumann [@CR24_5]). An alternative approach was developed in the Curtiss lab which was named "regulated delayed synthesis of antigens" (Xin et al. [@CR232_5]). Here, antigen production is retarded due to the arabinose-dependent expression of a repressor protein driven by the P~BAD~ promoter in vitro (Guzman et al. [@CR87_5]). Upon vaccine administration, the repressor expression ceases due to the lack of arabinose in the gastrointestinal tract of the mice, thus relieving the repressor blockade of the antigen expression cassette. For both strategies, the use of IVI promoters or the employment of a regulated delayed synthesis system, the time point of antigen synthesis and the expression level is fixed and cannot be tuned during vaccination. We therefore have recently tested the suitability of substrate-inducible promoters for the deliberate onset and adjustment of reporter gene expression by bacterial LAV in vivo (Loessner et al. [@CR140_5], [@CR142_5]). Such promoters constitute a new option for inducible antigen expression in a controlled manner in vivo, a concept that was termed "in vivo remote control" (IVRC). However, since for optimal induction of immune responses, such as Th1-type responses, continuous antigen expression is necessary (Griffin and McSorley [@CR82_5]), prolonged administration of inducer substrate would probably be required when IVRC promoters are employed.

### Expression Cassette {#Sec6_5}

Plasmids harboring expression cassettes are often used for conversion of vaccine strains into delivery vehicles for heterologous antigens. The main advantage of plasmids is that they can be easily manipulated in *E. coli* and subsequently transferred into vaccine strains. In addition, multicopy plasmids mediate elevated levels of antigen synthesis in comparison to single-copy chromosomal expression cassettes. However, episomal plasmid replication constitutes a metabolic burden for bacteria, thus further attenuating the vaccine strain (Covone et al. [@CR41_5]). Moreover, plasmid maintenance is often achieved by antibiotic selection in vitro. In the absence of this selective pressure in vivo, plasmids are often lost from the proliferating bacteria. In order to ensure stability of the plasmid transformants without the need of antibiotic selection, so-called balanced lethal systems have been established (Curtiss III et al. [@CR45_5]). Such systems rely on host strains with a chromosomal deletion of an essential metabolic gene. The defect of this gene is complemented on the expression plasmid, therefore ensuring stable plasmid propagation. An alternative approach is the use of so-called addiction systems for plasmid stabilization (Galen et al. [@CR69_5]).

In contrast, integration of expression cassettes into the bacterial genome ensures stable propagation. However, genomic integration of single expression cassettes often does not mediate synthesis of sufficient antigen levels. A solution to this problem would be multiple integrations of the same expression cassette. However, in recombination competent vaccine strains such repetitions of homologous sequences are often instable due to undesired recombination events. In accordance, removal of recombinases from vaccine strains is an important advancement for the stabilization of such repetitive chromosomal integrations and also plasmid DNA (Zhang et al. [@CR237_5]).

Nowadays, gene synthesis is rapidly replacing cloning procedures for the establishment of antigen expression cassettes (Kindsmuller and Wagner [@CR110_5]). Thus, the fine tuning of promoter elements or the optimization of coding sequences, e.g., the adjustment of codon usage, has been accelerated tremendously.

### Antigen Release {#Sec7_5}

Several properties of the vaccine strain, such as cellular tropism, bacterial virulence mechanisms, and type of attenuation, predetermine the time point and location of antigen delivery (Fig. [5.2](#Fig2_5){ref-type="fig"}) (Cheminay and Hensel [@CR32_5]; Loessner et al. [@CR141_5]). Since requirements for protective immune responses against pathogens differ, targeting of heterologous antigens into different presentation pathways is necessary. Thus, the choice of the right attenuated vaccine strain is important to accomplish such efficient targeting. Heterologous antigens synthesized by bacterial LAV have to be released from the bacteria in order to be recognized by immune cells. Gram-negative bacteria lacking gene *asd* encoding the aspartate-semialdehyde dehydrogenase undergo cell death in environments lacking diaminopimelic acid (DAP). Since DAP is absent in the gastrointestinal tract, orally applied bacteria deficient of *asd* quickly lyse in vivo (Curtiss III [@CR43_5]). During DAP-less death, the bacterial cell wall spontaneously bursts, and cytoplasmic cellular contents such as protein and nucleic acids are efficiently released (Loessner et al. [@CR139_5]). In contrast, other lethal attenuations, such as deficiency of *thyA* (thymidylate synthase) in thymine or thymidine-deprived environments, do not cause rupture of the bacterial cell, and therefore, no immediate release of cytoplasmic material occurs. Hence, subsequent slow degradation of bacterial carcasses may prevent release and presentation of heterologous antigen. As alternative to strain attenuation, inducible lysis systems have been developed which mediate efficient release of cytoplasmic antigen or nucleic acid from ruptured bacterial cells. For instance, bacteriophage lysis determinants have been employed for this purpose (Jain and Mekalanos [@CR101_5]). The use of lysis protein E derived from phage phiX174 has already been employed for some time to prepare bacterial cell envelopes devoid of cytoplasmic content to be used for vaccination, so-called bacterial ghosts (Jalava et al. [@CR102_5]). The employment of such lysis determinants for the release of heterologous antigens from a bacterial vector strain necessitates its tightly regulated inducible expression in vivo. This was achieved by linking lysis gene *E* to the arabinose-inducible P~BAD~ promoter, suitable for IVRC (see above) (Loessner et al. [@CR140_5]), or more recently to quorum sensing or iron-regulated promoters (Guan et al. [@CR84_5]; Silva et al. [@CR198_5]). Similar to DAP-less death, lysis protein E causes rupture of bacterial cells by interference with cell wall synthesis (Bernhardt et al. [@CR16_5]).

Another lysis strategy was established by the Curtiss lab, termed "regulated delayed lysis system" (Kong et al. [@CR115_5]). In this work, a *Salmonella* double mutant strain was constructed with chromosomal deletions of two genes involved in cell wall biosynthesis, *asd* and *murA*. Plasmid-encoded complementing genes are linked to the arabinose-inducible P~BAD~ promoter which was kept active by the presence of arabinose during culture. Upon oral vaccine administration, expression of both genes ceases due to absence of arabinose in vivo and bacteria disintegrate. Thus, this system confers attenuation and mediates antigen release at the same time.

Whereas cytoplasmic antigens are released at once from bacteria undergoing lysis, a viable bacterial carrier can be engineered to release antigen continuously by the use of a suitable secretion system. A variety of one-component or multicomponent secretion systems have been employed for this task. As single-component systems, so-called autotransporters, such as *E. coli* AIDA-I (Maurer et al. [@CR152_5]), are suitable for translocation of passenger antigens across the gram-negative cell envelope. Stable display of antigens on the surface of a *Salmonella* vaccine strain via the *E. coli* AIDA-I efficiently induced cellular immune reactions (Kramer et al. [@CR118_5]).

Similarly, the *E. coli* alpha-hemolysin (HlyA) secretion apparatus, belonging to the group of type I secretion systems, is fully active in *Salmonella* vaccine strains and has successfully been used for the delivery of a number of antigens (Gentschev et al. [@CR72_5]). The system is composed of three proteins which mediate translocation of passenger antigens fused to the HlyA signal peptide directly to the extracellular medium.

So-called type III secretion systems (T3SS) are used by bacterial pathogens for the delivery of virulence factors across eukaryotic membranes (Hueck [@CR98_5]). T3SS are very complex and cannot easily be transferred from one bacterial vector to another. However, naturally T3SS harboring vaccine strains can be efficiently subverted for the delivery of antigens directly into the cytosol of host cells (Russmann et al. [@CR187_5]). This way, antigens can be targeted into MHC-I presentation pathway by extracellular or phagosome-restricted bacterial vectors (Russmann et al. [@CR188_5]; Panthel et al. [@CR175_5]). Nevertheless, the specificity of the T3SS for particular virulence factors renders these systems difficult for a general application of antigen secretion by gram-negative bacterial vaccine strains. In contrast, secretion systems from gram-positive bacteria are often less restricted to particular virulence factors and might allow the continuous secretion of antigens from the vaccine carrier (Buist et al. [@CR23_5]).

### Delivery of Nucleic Acid Vaccines {#Sec8_5}

Already some time ago, the capability of bacteria to deliver nucleic acids into mammalian cells was discovered (Schaffner [@CR193_5]). Meanwhile, bacteria-mediated transfer of plasmid DNA encoding vaccine antigens or therapeutic molecules was demonstrated in experimental animal models of infectious diseases, tumors, and gene deficiencies (Becker et al. [@CR15_5]; Daudel et al. [@CR50_5]; Loessner and Weiss [@CR137_5]). Bacteria, competent to access the host cell cytoplasm, have been observed to display the highest transfer efficiency for nucleic acids (Courvalin et al. [@CR40_5]; Dietrich et al. [@CR54_5]; Sizemore et al. [@CR201_5]). However, bacteria restricted to an intracellular vacuolar compartment such as *Salmonella* are also capable to mediate DNA transfer to a certain extent by an unknown mechanism (Darji et al. [@CR49_5]). The use of an *S. typhimurium* strain lacking *ssrAB*, two essential genes for maintenance of phagosomal integrity during intracellular growth, improved the DNA delivery capacity of the vaccine strain (Bai et al. [@CR10_5]). In addition, extracellular bacteria can mediate DNA delivery into mammalian cells by a conjugational apparatus (Kunik et al. [@CR120_5]; Waters [@CR223_5]). In comparison to other DNA delivery systems, bacterial vectors have a nearly unlimited capacity with regard to size. For instance, infectious virus could be reconstituted by the delivery of the complete genome of murine cytomegalovirus (MCMV) by a *Salmonella* vaccine strain into mammalian cells (Cicin-Sain et al. [@CR34_5]). Specific silencing of mammalian genes was achieved with an engineered *E. coli* strain which could mediate the delivery of short hairpin RNA (shRNA) (Xiang et al. [@CR231_5]). However, several bottlenecks have been identified which counteract the bacterial delivery of nucleic acids into mammalian cells. Cellular defense mechanisms such as autophagy (Ogawa et al. [@CR172_5]), bacteria-induced cellular activation, or cell death (Fink and Cookson [@CR61_5]) are factors that can restrict transfer efficiency. Nevertheless, bacteria-mediated gene transfer remains an attractive alternative for antigen delivery. Since the antigen is produced by the eukaryotic cells, obstacles like inefficient protein folding, posttranslational modification, or secretion can be circumvented. In addition, the bacteria represent a powerful adjuvant that helps to trigger efficacious immune responses.

### Delivery of Tumor Vaccines and Adjuvant Molecules {#Sec9_5}

The best examples for successful bacteria-mediated DNA vaccination are the experiments by the Reisfeld group using oral *Salmonella* vectors for delivery of anticancer vaccines (Reisfeld et al. [@CR183_5]). Vaccine-mediated restriction of tumor angiogenesis was one approach of this work. As one of their targets, they used the vascular endothelial growth factor receptor (VEGFR2), also referred to as FLK-1. This molecule is not expressed by tumor cells but highly expressed on endothelial cells of growing tumor capillaries. When a eukaryotic FLK-1 expression plasmid was transferred orally by *Salmonella* to mice, animals were protected against subsequent challenge with different tumors, such as the MC38 colon carcinoma (Niethammer et al. [@CR170_5]). Even 10 months after the vaccination, animals could resist such a challenge. Also, the use of so-called minigenes for expression of FLK-1 epitopes was successful to restrict tumor growth due to CD8 T-cell response (Luo et al. [@CR146_5]). The advantage of such minimal coding sequences is that the probability of mutations is reduced and antigen delivery by bacteria is facilitated.

Another possible strategy is the use of a DNA vaccine for co-expression of cytokines or chemokines in conjunction with the antigen. IL-18 is a multifunctional cytokine and is able to improve tumor antigen presentation by DCs. Co-expression of the tumor antigen Fos-related antigen (Fra-1), which is overexpressed by many epithelial carcinomas, together with IL-18 mediated the reduction of metastases (Luo et al. [@CR145_5]). In another approach, inhibition of angiogenesis was achieved by *Salmonella*-mediated oral delivery of the apoptosis protein survivin and the chemokine CCL21 in parallel, which attracts activated DCs and naïve T cells to the tumor site. Vaccination prevented pulmonary tumor growth and metastases and reduced the growth of already established tumors (Xiang et al. [@CR230_5]). The expression of fibroblast activation protein (FAP) can be determined in approximately 90% of human epithelial tumors and is specific for stromal fibroblasts in solid tumors. The *Salmonella*-mediated delivery of a DNA vaccine against FAP enhanced the efficacy of doxorubicin chemotherapy and suppressed spontaneous metastases. In addition, this combination therapy inhibited tumor angiogenesis and reduced the expression of proliferative factors by the tumor microenvironment (Liao et al. [@CR130_5]).

Attenuated strains of the gram-positive bacteria *L. monocytogenes* have also been studied in context of tumor vaccines. The bacteria are able to infect phagocytic and nonphagocytic cells and can spread in the body without being attacked by an antibody response. *L. monocytogenes* infection stimulates strong innate and adaptive immune response, rendering it an efficient vaccine vector candidate (Barbuddhe and Chakraborty [@CR11_5]). In addition, the cytosolic intracellular residence of the bacteria favors a CD8 T-cell response that is necessary for the generation of antitumor immunity. To ensure bacterial secretion of the specific antigen, in most cases, the antigen is fused to a secretory bacterial protein such as LLO. One example of a *L. monocytogenes* tumor vaccine is a strain producing the human papillomavirus (HPV) antigen E7, which is associated with cervix and head and neck cancer (Gunn et al. [@CR86_5]). In animals, this vaccine induces immune responses against E7 and causes regression of tumors which express the E7. In a phase I clinical trial, this vaccine was demonstrated to be safe in humans (Maciag et al. [@CR148_5]). From 13 patients, five had progressed, seven had stable disease, and one qualified as a partial responder. Increased survival of patients was observed, from 180 to 347 days, and three patients were still alive 3 years after treatment. *L. monocytogenes* was also employed for the delivery of a prostate cancer vaccine. *L. monocytogenes* was engineered to deliver a LLO--PSA fusion protein. In a mouse model, it was demonstrated that this vaccine is immunogenic and causes regression of established PSA-expressing tumors (Shahabi et al. [@CR196_5]).

Tumor-Targeting Bacteria {#Sec10_5}
------------------------

Apart from being powerful carriers for novel vaccination strategies, particular bacteria show also a potential to be used in cancer therapy. This is due to their ability to target and colonize tumors upon systemic administration (Leschner and Weiss [@CR126_5]). Among the bacteria able to target tumors are anaerobics like *Clostridia* and *Bifidobacteria* as well as facultative anaerobics like *Salmonella* and *E. coli*. Interestingly, already in the nineteenth century, several physicians observed that cancer patients who caught an infection sometimes were cured from the tumor (Coley [@CR35_5]). Even intentional infection of cancer patients mediated successful tumor cure in some cases; however, in most patients, the infection was fatal, and therefore, this approach was abandoned at that time. Today, with new options for attenuation and programming of bacteria, the development of cancer therapeutics based on living bacteria should become feasible.

Since most bacterial strains used for cancer therapy are pathogens, they first of all have to be attenuated. Some strains are under investigation that have been tested already as vaccine carriers like SL7207 (*ΔaroA, ΔhisG*) (Leschner et al. [@CR127_5]; Westphal et al. [@CR225_5]; Yu et al. [@CR235_5]), BRD509 (*ΔaroA, ΔaroD*) (al-Ramadi et al. [@CR4_5]; Yoon et al. [@CR234_5]), and SL3261AT (*ΔaroA*) (Avogadri et al. [@CR8_5]; Yang et al. [@CR233_5]). Such strains are deficient in synthesis of aromatic amino acids. Besides, there are also strains attenuated especially for the tumor-targeting purpose. One example is the *Salmonella* strain A1-R that was rendered auxotrophic for leucine and arginine and reisolated from tumors to enhance tumor specificity. It colonizes various human tumors and metastases in nude mice but is cleared rapidly from other organs (Hayashi et al. [@CR90_5]; Hayashi et al. [@CR91_5]; Kimura et al. [@CR109_5]; Nagakura et al. [@CR166_5]; Zhao et al. [@CR240_5], [@CR238_5], [@CR239_5]). Another *Salmonella* strain considered to display an improved safety profile is VNP20009 (*ΔpurI, ΔmsbB*). It produces a modified lipopolysaccharide and thus induces dramatically diminished levels of TNF-α in human peripheral leukocytes (Low et al. [@CR144_5]). Unfortunately, VNP20009 did not readily colonize tumors of patients in phase I trials (Heimann and Rosenberg [@CR92_5]; Toso et al. [@CR212_5]). Possibly this strain is overattenuated since TNF-α was shown to play an important role in the invasion process of *Salmonella* into tumors (Leschner et al. [@CR127_5]). Thus, presently, the major challenge in developing tumor-targeting bacteria is proper attenuation of the strain without restricting its capability to colonize the tumor tissue.

Apart from their inherent antitumor effect, some bacteria could be used as carriers to deliver therapeutic agents directly into the cancerous tissue. Different classes of molecules have been tested. One class represents immune modulatory molecules that should enhance the immune response toward the tumor or directly kill cancer cells. IL-2, IL-18, CCL21, LIGHT, and Fas ligand have been tested in this context (al-Ramadi et al. [@CR3_5], al-Ramadi et al. [@CR4_5]; Loeffler et al. [@CR133_5], Loeffler et al. [@CR134_5], [@CR135_5], [@CR136_5]; Saltzman et al. [@CR190_5], [@CR191_5]; Sorenson et al. [@CR202_5], [@CR203_5]). Toxic agents are another possibility to enhance anticancer effects of bacteria. For instance, the bacterial toxin cytolysin A resulted in strong reduction of tumor growth when expressed by tumor-colonizing *S. typhimurium* (Nguyen et al. [@CR169_5]; Ryan et al. [@CR189_5]). A third class of molecules are so-called prodrug-converting enzymes that convert nontoxic prodrugs into toxic substances. For example, thymidine kinase of the herpes simplex virus or *E. coli* cytosine deaminase has been used in this context (King et al. [@CR111_5]; Nemunaitis et al. [@CR168_5]; Pawelek et al. [@CR179_5]; Royo et al. [@CR186_5]). Tumor therapeutic bacteria mediating delivery of eukaryotic expression plasmids for therapeutic factors or interfering RNA species are also in development. In tumor therapeutic approaches, the use of proteins like thrombospondin-1, endostatin, Fms-like tyrosine kinase 3 (Flt3) ligand, but also the *E. coli* prodrug-converting enzyme purine nucleoside phosphorylase or apoptosis-inducing proteins (TRAIL and Smac), led to efficient treatment of various tumors in mice (Fu et al. [@CR65_5], [@CR66_5], [@CR67_5]; Lee et al. [@CR122_5], [@CR123_5]; Yoon et al. [@CR234_5]). Similarly, siRNAs on eukaryotic plasmids targeting Stat-3 or the antiapoptotic protein bcl-2 showed their potential to be used in the treatment of tumors. Although promising, the mechanism leading to the effect is unclear. *Salmonella* are only rarely found inside of tumor cells or other host cells (Agorio et al. [@CR1_5]; Loessner and Weiss [@CR138_5]; Pawelek et al. [@CR179_5]). Therefore, the question which cells can be the target for gene transfer still has to be answered. When constructing an efficacious anticancer bacterium, the regulation of therapeutic molecule expression is crucial. The use of particular promoters allows to predetermine the exact onset of therapeutic treatment as well as its termination, e.g., via the expression of suicide genes (Loessner et al. [@CR140_5]). Therefore, inducible promoters like the P~BAD~ promoter mentioned before enable to start the expression upon administration of the inducer substance at any desired time point (Loessner et al. [@CR140_5]). Furthermore, tumor-specific promoters that exclusively drive protein expression inside of the neoplasia but not in any other tissue of the host are an important aspect to avoid side effects on healthy organs (Arrach et al. [@CR7_5]; Leschner et al. [@CR250_5]). Bacteria-mediated tumor therapy is often met with skepticisms despite the undisputed success in experimental and preclinical models. Although it will still require many iterative steps until it is converted into a general applicable therapeutic strategy, it undoubtedly has great potential. That certain tumors in human patients are colonized by bacteria demonstrates that future implementation of such a therapeutic option is realistic.

Live Attenuated Viral Vaccines and Viral Vaccine Vectors {#Sec11_5}
========================================================

Classical Viral Vaccines {#Sec12_5}
------------------------

Almost all human and veterinary vaccines against viral diseases which are in use today are live attenuated or inactivated virus vaccines. Live virus vaccines are either derived from related low pathogenic viruses which enable cross-protection against the highly pathogenic virus strains (like the cowpox or vaccinia virus for vaccination against variola virus that causes smallpox) or derived by undirected attenuation of the viruses. Since they were all developed at a time when knowledge about the virus genomes and mechanisms of virulence were still lacking, mutagenesis of viruses was relatively random. In the past, attenuation of a virus was achieved by passaging in embryonated eggs or in animals of different vertebrate species followed by cell culture adaption. Later, with the establishment of standardized cell culture techniques, live virus vaccines were propagated in primary cells like chicken embryonic fibroblasts and human diploid cell lines (e.g., MRC-5) which have a definite life span. To facilitate the process of vaccine production, these cells are now successively being replaced by continuous cell lines (CCLs) due to improved characterization of these cells and widened analytical technologies able to determine their possible oncogenic potential. Thus far, only a small number of human vaccines are produced in CCLs (Gregersen et al. [@CR81_5]). The African green monkey kidney cell line Vero is now the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines (Barrett et al. [@CR12_5]). Furthermore, vaccine manufacturers of seasonal and pandemic influenza vaccines are at various stages of developing cell-derived vaccines (Pandey et al. [@CR174_5]). Vero cells or Madin-Darby canine kidney (MDCK) cells are often the CCLs of choice (Govorkova et al. [@CR80_5]; Hu et al. [@CR97_5]).

Current live viral vaccines are attenuated strains of poliovirus as well as measles, mumps, or rubella virus. In some countries, the latter are given as triple vaccine, called the MMR vaccine. These vaccines have been applied successfully and brought the world closer toward eradication of additional viral diseases, besides smallpox. Thus far, polio is eliminated from most parts of the world. Some European countries claim the eradication of measles virus. These achievements were possible because these viruses are restricted to the human host and do not persist in an animal reservoir. In addition, only one viral serotype (variola, mumps, measles, rubella) or very few serotypes (polio) exist. Thus, it is possible to induce protective antibody titers with a relatively simple vaccine composition. T-cell immunity is only known to play a role in the induction of protective immunity against measles virus (Griffin and Pan [@CR83_5]), while the role of T cells for immunity against other viruses is still not clear.

Unfortunately, some countries still remain endemic for measles virus due to various factors, such as political problems, inappropriate health care systems, socio-ethical reasons, or inherent biological characteristics of the virus (Chumakov et al. [@CR33_5]). However, also in some industrialized countries, compliance with routine vaccination of children has ceased to some extent. Hence, efforts of politics and health care professionals on the one hand and also the development of new vaccines are necessary in order to achieve the goal of global eradication of such viruses. For example, research on measles vaccines now includes also the development of DNA vaccines, subunit vaccines, and virus-vectored vaccines (Griffin and Pan [@CR83_5]). Furthermore, the development of robust vaccines and simple application procedures is of great importance. In this regard, the development of thermostable vaccines or vaccines for needle-free application, e.g., aerosol administration, is in progress (Higginson et al. [@CR93_5]). Moreover, the safety of measles vaccine in HIV-infected persons has to be improved (Strebel et al. [@CR206_5]). Eradication of poliovirus was almost achieved using the trivalent polio vaccination. However, now, the monovalent oral polio vaccine (OPV) or inactivated polio vaccine (IPV) shall enable the complete eradication of polio (Ehrenfeld et al. [@CR59_5]). Many live vaccines are in use for livestocks like bovine respiratory syncytial virus for cattle or calicivirus in cats. Thus far, the most successful live viral vaccine is the "Rinderpest" vaccine. It has succeeded to completely eradicate the disease in 2011.

The use of an inactivated virus as vaccine is an alternative to the application of viral LAV. One advantage is that pathogenic viral isolates can be used. Today, inactivated vaccines are produced against tick-borne encephalitis virus, hepatitis A virus, seasonal influenza, Japanese encephalitis virus, rabies and yellow fever, and a spectrum of veterinary viral diseases. Inactivated vaccines have the advantage of increased safety since they are not able to replicate in cells of the vaccinated host and therefore do not spread to contacts. However, due to their replication deficiency, such vaccines stimulate mainly antibody responses. Moreover, during the inactivation process, e.g., the action of formaldehyde, the antigenicity of the vaccine might be reduced due to the destruction of protective epitopes (Fraenkel-Conrat and Mecham [@CR63_5]; Metz et al. [@CR160_5]). Thus, inactivated viruses often do not reach the same efficacy as live attenuated virus, and a protective immune response is not always elicited (Fig. [5.3](#Fig3_5){ref-type="fig"}).

The efficacy obtained with live virus vaccines in some cases prevented further development of inactivated vaccines. However, the use of adjuvants, alternative inactivation procedures, or vaccine compositions may allow the generation of new inactivated vaccines with increased efficacy, able to induce antibody as well as T-cell-mediated immune responses (Amanna and Slifka [@CR5_5]). Nevertheless, despite improved safety requirements, research on live attenuated viruses is also maintained. For instance, a cold-adapted seasonal influenza vaccine has recently been approved in the USA (Kreijtz et al. [@CR119_5]).

Recombinant Antiviral Subunit Vaccines {#Sec13_5}
--------------------------------------

Recombinant biotechnology allowed the development of two successful viral subunit vaccines for humans, against the hepatitis B virus (HBV) and the human papillomavirus (HPV). The HBV vaccine was registered in 1984. It is highly protective and reduced in endemic areas dramatically hepatocellular carcinoma that is a sequel of chronic HBV infection. The HBV vaccine is produced in yeast or mammalian CHO cells and consists of a recombinant surface protein of the virus, the HBsAg (McAleer et al. [@CR156_5]; WHO [@CR226_5]). The two major yeast-derived hepatitis B vaccines that are licensed in most countries are given as a monovalent vaccine; however, formulations with a hepatitis A vaccine are also available (Previsani and Lavanchy [@CR181_5]). The HPV vaccine is directed against virus-induced cervical cancer, some vulvar and vaginal cancers and some genital warts in young women and men. Two prophylactic HPV vaccines were approved in Europe and the USA in 2007. They both target the HPV serotypes 16 and 18 or additionally 6 and 11 and consist of the yeast or insect cell-produced shell L1 protein that self-assembles into virus-like particles (GlaxoSmithKline [@CR75_5]; Merck&CO [@CR159_5]; WHO publication [@CR227_5]).

Recombinant Viral Vectors for Novel Vaccine Developments {#Sec14_5}
--------------------------------------------------------

Vaccines against a range of viral diseases are not yet available. This does not only concern new emerging viruses like West Nile virus or newly arising pandemic influenza viruses, e.g., H5N1 or H1N1, but also HIV and zoonotic viruses. Such viruses often establish quickly a quasi-species in the host with a variant serology as an immune escape mechanism against host immune surveillance. This unfortunately includes vaccine-induced immunity, making conventional vaccine development extremely difficult. Thus, novel vaccines based on recombinant microbes define nowadays future developments to conquer such diseases. Different viruses are now exploited for the development of recombinant vaccines that include members of the family of poxvirus, adenovirus, lentivirus, retrovirus, alphavirus, rhabdovirus, as well as vesicular stomatitis virus (Fig. [5.4](#Fig4_5){ref-type="fig"}). Here, the virus builds the backbone of a prophylactic or therapeutic vaccine for the delivery of heterologous antigens. The large panel of different viruses exhibiting different features provides the possibility to exploit diverse immune-stimulating capacities as well as the potential to deliver antigens to different immune inductive sites. Together with prime--boost applications as well as adjuvant delivery, a wide range of possibilities are provided to suffice requirements to fight many particular diseases.Fig. 5.3*From naked adjuvanted vaccines to live viruses---the balance between genetic complexity, strong immune response, and safety*. There is an intrinsic mismatch between safety on the one side and potent immune induction translating into protection on the other side. Highly attenuated replication-defective viral vectors have been developed as a system balancing the benefit of maximized immunogenicity and strongest safety. *AS01* adjuvant system 01, *MF59* oil-in-water emulsion adjuvant, *VLP* virus-like particle, *AdV* adenovirus, *MVA* modified vaccinia virus Ankara, *AAV* adeno-associated virus, *VEE* Venezuelan equine encephalitis virus

Several recombinant vaccines have been successfully introduced into the veterinary practice. Canarypox and fowlpox vector vaccines, baculovirus-expressed viral antigens, and even DNA vaccines build the second generation of licensed veterinary vaccines (Meeusen et al. [@CR157_5]). Vector vaccines for humans are not yet approved, but promising preclinical and clinical data have been obtained and will be discussed below.

### Attenuated Vaccinia Viruses {#Sec15_5}

During the vaccination campaign against smallpox, severe side effects were tolerated. Such side effects included generalized vaccinia, unwanted spreading to unprotected contact persons, or even life-threatening reactions like eczema vaccinatum, vaccinia necrosum, and postvaccinal encephalitis. However, despite sporadic occurrence of zoonotic poxvirus infections and the threat of bioterrorism today, such side effects are nowadays intolerable. Therefore, besides the continuous use of the vaccinia virus (VACV) vaccine Dryvax for certain person groups in the USA, attenuated strains have been developed. These are the modified vaccinia virus Ankara (MVA) derived from the chorioallantois virus strain Ankara (Mayr et al. [@CR153_5]), the New York VACV (NYVAC) based on the Copenhagen strain of VACV (Tartaglia et al. [@CR210_5]), and LC16m8 derived from the VACV Lister strain (Kenner et al. [@CR108_5]).

Like conventional VACV, MVA and NYVAC potently induce humoral and cellular immune responses. However, these vaccines considerably differ in their immune-stimulating capacity. MVA was generated by passaging the virus more than 500 times in chicken embryonic fibroblasts, whereby it gained many deletions and point mutations resulting in the loss of about 15 kb of DNA in comparison to its parental strain. In contrast, NYVAC received deletions of 18 particular genes. In both viruses, the function of several immune suppressive genes was lost. As a result of their genetic diversity, MVA and NYVAC differentially stimulate the immune response of the host. For example, distinct gene expression profiles were induced upon infection of human monocyte-derived dendritic cells (Guerra et al. [@CR85_5]; Najera et al. [@CR167_5]). Moreover, a parallel comparison of both vectors to determine vaccine efficacy in a macaque HIV model showed a more CD4+ T-cell-driven immune response for NYVAC, whereas MVA induced CD8+ as well as CD4+ T-cell responses to the heterologous vaccine antigens (Mooij et al. [@CR163_5]). The molecular and immunological basis of innate and adaptive immune stimulation of these viruses is now under intense investigation. Interestingly, MVA has a unique ability to induce type I interferons and a spectrum of chemokines and cytokines in contrast to VACV (Guerra et al. [@CR85_5]; Lehmann et al. [@CR125_5]; Waibler et al. [@CR220_5]).

Due to their genomic deletions, MVA and NYVAC have lost the capacity to replicate in most mammalian cells and consequently cannot spread in vivo (Drexler et al. [@CR58_5]; Gomez et al. [@CR77_5]; Meyer et al. [@CR161_5]; Tartaglia et al. [@CR210_5]). Both viruses were tested in several animal models and found to be highly attenuated in comparison to VACV. Moreover, MVA has already been used in humans. It was proven to exhibit an excellent safety profile when applied to 120,000 humans including high-risk patients still during the poxvirus eradication program (Mayr et al. [@CR154_5]). Later, several phase I clinical trials with different MVA vector vaccines administered at high doses confirmed this safety profile of MVA (Goepfert et al. [@CR76_5]; von Krempelhuber et al. [@CR219_5]; Wilck et al. [@CR228_5]). In comparison with other viral vectors, it is of note that MVA and NYVAC like other poxviruses replicate exclusively in the cytoplasm of infected cells making a gene transfer event into the host cell genome unlikely.

Despite the lack of productive infection, MVA and NYVAC exert a full gene expression profile and are suitable to mediate high-level production of recombinant antigens (Sutter and Moss [@CR207_5]; Tartaglia et al. [@CR210_5]). Well-defined protocols for generation of recombinant viruses are established using homologous recombination technology and plaque selection with the help of different marker genes (Carroll and Moss [@CR27_5]; Staib et al. [@CR204_5]). More recently, recombinant VACV and MVA vaccines have been generated by the use of bacterial artificial chromosomes which further simplifies the construction of vector vaccines (Cottingham et al. [@CR39_5]; Domi and Moss [@CR56_5]). The viruses tolerate large inserts of foreign sequences into their double-stranded DNA genomes and are normally very stable. MVA can be produced in large amounts and can even be used as dried vaccine. Thus, it will be suitable also for the application in areas where the cooling chain cannot be guaranteed. In addition, mucosal needle-free application of freeze-dried MVA into mice clearly demonstrated the potency of this formulation to induce immune responses comparable to parenteral application. Protection against lethal bacterial and viral challenges was generated this way (Kastenmuller et al. [@CR103_5]). These features proof recombinant MVA or VACV to be simple and safe vaccine platforms for general application. Both MVA and NYVAC were developed as vector vaccines against a diverse set of infections, cancer, and allergic diseases. Besides the use of MVA directly as poxvirus vaccine, MVA-based vector vaccines against HIV, malaria, and different cancers and allergies are investigated preclinically and also in clinical phase I and/or II trials (Albrecht et al. [@CR2_5]; Gomez et al. [@CR78_5]).

### Avipoxviruses {#Sec16_5}

Canarypox and fowlpox are avipoxviruses which have been used since some time as vector vaccines. Both avipoxviruses have a strict host tropism to birds but contain the ability to infect mammalian cells and strongly express heterologous antigens without completion of the virus life cycle. This constitutes an important safety feature for these live attenuated virus vectors. Canarypox was shown to elicit humoral and cellular immune responses in vaccinated subjects (Zanotto et al. [@CR236_5]). Interestingly, recombinant canarypox was found being able to induce a 100-fold stronger protective immune response compared to a similar fowlpox vaccine (Taylor et al. [@CR211_5]). Today, several canarypox-based veterinary vaccines are in routine use (Poulet et al. [@CR180_5]), of which most are based on the ALVAC strain, a plaque isolate of the canary vaccine Kanapox. For humans, an ALVAC-based HIV vaccine (ALVAC-HIV, vCP1521) expressing the glycoprotein gp120 of clade B/E is currently tested in a phase III clinical trial (Rerks-Ngarm et al. [@CR184_5]). In contrast to a trial where the recombinant vaccine was given alone, a prime--boost regimen together with a recombinant HIV glycoprotein subunit vaccine (AIDSVAX) gave encouraging results. In this efficacy trial performed in Thailand, HIV acquisition was significantly reduced in the vaccine group (Vaccari et al. [@CR213_5]).

### Measles Viruses {#Sec17_5}

Measles virus, also known as rubeola or morbilli, is an enveloped, single-stranded, negative-sense RNA virus which infects the respiratory system. It belongs to the family *Paramyxoviridae* of the genus *Morbillivirus*. In developed countries, most children are immunized against measles. However, worldwide, approximately 200,000 children die of measles each year. Immune responses induced by routine vaccination represent a problem for the use of recombinant measles vector vaccines. On the other hand, the extensive clinical experience with the adapted measles vaccines, their rare side effects, and their capacity to induce a strong often lifelong immunity renders measles virus highly suitable as a vaccine vector. To use a nonsegmented negative-strand RNA virus (Mononegavirales) as vector is possible nowadays by state-of-the-art molecular methods to produce cDNA clones. These technologies allow site-directed mutagenesis to study gene functions as well as to insert foreign coding sequences to develop multivalent vaccines against measles and other pathogens. The use of measles virus as vector was experimentally promoted by its high genetic stability, which is unexpected for RNA viruses, and by its acceptance of foreign sequences. For quite a while, it was not possible to convert measles virus into a vaccine vector, but in the meantime, appropriate replicons, helper cells, and helper viruses were constructed (Collins et al. [@CR37_5], [@CR36_5]; Conzelmann and Schnell [@CR38_5]; Martin et al. [@CR151_5]; Schneider et al. [@CR195_5]; Sidhu et al. [@CR197_5]; Takeda et al. [@CR208_5]). The newly developed systems allow the insertion of additional transcription units for heterologous antigens. The maximal insertion capacity tolerated by the virus is 6 kb, and expression level of the inserted gene depends on the position within the viral genome (Billeter et al. [@CR17_5]; Hangartner [@CR88_5]; Singh et al. [@CR199_5]; Wang et al. [@CR222_5]; Zuniga et al. [@CR241_5]). Measles-based vector vaccines are considered as candidates for multivalent vector vaccines expressing antigens of hepatitis B (del Valle et al. [@CR52_5]; Singh et al. [@CR199_5]), SIV/HIV (Brandler and Tangy [@CR20_5]; Lorin et al. [@CR143_5]; Tangy and Naim [@CR209_5]; Wang et al. [@CR222_5]; Zuniga et al. [@CR241_5]), West Nile, Dengue virus (Brandler and Tangy [@CR20_5]; Despres et al. [@CR53_5]), and SARS coronavirus (Liniger et al. [@CR132_5]). Several studies in mouse models have shown that recombinant measles vaccines are capable of inducing humoral immunity against both measles and heterologous antigens (de Vries et al. [@CR51_5]). The first candidate vaccine "HIV-measles," which was developed in the last few years by the Tangy group at the Pasteur Institute, should enter soon into the clinical testing phase.

### Yellow Fever Virus {#Sec18_5}

Yellow fever is an acute viral hemorrhagic disease caused by an enveloped, single-stranded, positive-sense RNA virus of the *Flaviviridae* family. Surviving an infection by yellow fever virus results in lifelong immunity, and normally no permanent organ damage is encountered in such individuals (Schmaljohn and McClain [@CR194_5]). The original yellow fever vaccine is a live attenuated virus based on the 17D yellow fever virus strain (YFV-17D). It was developed almost 70 years ago by empirical methods and is still considered to be one of the safest and most effective virus vaccines. Starting from this vaccine, live attenuated chimeric viruses were constructed by replacing the genes coding for premembrane (prM) and envelope (E) proteins of the YFV-17D vaccine strain with such of heterologous flaviviruses (ChimeriVax technology) or the gene Japanese encephalitis virus (JE) encoding the JE preM--Env protein (Draper and Heeney [@CR57_5]). The latter chimera has completed phase III trials and is currently in preregistration. The JE vaccine, previously known as ChimeriVax-JETM, is supposed to become the first approved human viral vector vaccine (Appaiahgari and Vrati [@CR6_5]).

### Adenoviruses {#Sec19_5}

Human adenoviruses belong to the family *Adenoviridae*. Viruses of this family infect both humans and animals. Adenoviruses are nonenveloped icosahedral viruses assembled from a nucleocapsid that harbors the double-stranded linear DNA genome. There are 53 serotypes of adenoviruses in humans with variable morphology (Kaufman [@CR104_5]). The virus is responsible for 5--10% of ocular, respiratory, or gastrointestinal epithelium infections in children and also adults. Already in 1977, a cell line was established that enabled the production of recombinant adenoviruses in a helper-free environment. Since this landmark, adenoviral vectors have received attention as gene transfer agents for gene therapy and for vector-based vaccinations (Randrianarison-Jewtoukoff and Perricaudet [@CR182_5]). Attenuation is usually achieved by deleting the E1A gene that is known to be essential for adenoviral replication (Carlock and Jones [@CR26_5]; Gaynor and Berk [@CR71_5]). The ΔE1A vectors are able to infect cells without causing any cellular damage. In the first vector generation, E1 and E3 were deleted (ΔE1/E3) because the E3 region is not essential for in vitro vector production. The adenovirus vector is able to deliver genes with nearly 100% efficiency to a wide range of cell types including dividing or nondividing cells as well as primary cells, and it is possible to produce extremely high viral titers. Adenoviral vectors provide a capacity of up to 8 kb of foreign recombinant genes. In the classical adenovirus vector generation, the recombinant genes are inserted into the deleted E1A region of a viral cDNA by in vitro ligation and homologous recombination protocols (Wolff and Lederberg [@CR229_5]). A new approach allows the generation of recombinant adenoviruses by Tn7-mediated transposition in *E. coli* (Richards et al. [@CR185_5]). For the viral production, normally modified 293 cells are utilized. These cells are stably transfected with the E1A region of the adenoviral genome and allow the vector to replicate and mature. The resulting vector particle prepared from this cell line will lack the E1A region and remain replication deficient. As with any viral vector system, it has to be ensured that the produced vector is not contaminated with the wild-type virus. In the adenoviral system, two homologous recombination events must occur to restore wild-type virus rendering this event highly unlikely.

Adenovirus vectors strongly induce the innate arm of the immune system that results in inflammation of infected tissues and efficient clearance of administered vectors (Muruve [@CR165_5]). Adenovirus vector vaccines are developed against a variety of different infectious diseases and have entered clinical trials for malaria (phase I), HIV-1 (Fitzgerald et al. [@CR62_5]), different cancers, and others malignancies (CR Health Net [@CR42_5]).

### Virus-Like Particles and Other Viral Vector Systems {#Sec20_5}

Virus-like particles (VLPs) are also considered as vector vaccines despite they are nonliving empty viral particles. These so-called pseudoviruses are noninfectious because they lack any viral genetic information which is normally packaged into such particles. For this technique, the capacity of viral structural proteins such as envelope or capsid to self-assemble into VLPs was exploited (Kirnbauer et al. [@CR113_5]; Kost and Condreay [@CR116_5]; Valenzuela et al. [@CR215_5]). VLPs of HBsAg derived from HBV were already described over 40 years ago from infected patient sera (Bayer et al. [@CR14_5]). Nowadays, VLPs are produced for the licensed HPV vaccine and additionally from a whole variety of other virus families including *Parvoviridae* (e.g., adeno-associated virus), *Retroviridae* (e.g., HIV), *Polyomaviridae* (e.g., JC virus) (Chang et al. [@CR29_5]), *Paramyxoviridae* (e.g., Nipah virus) (Walpita et al. [@CR221_5]), and *Flaviviridae* (e.g., hepatitis C virus). Despite their limited immune stimulatory capacity, VLPs are attractive vaccine candidates due to their higher safety level compared to LAV (Fig. [5.3](#Fig3_5){ref-type="fig"}). VLPs can be produced in different cell culture systems including mammalian and rodent cell lines, insect cell lines, yeast, and also plant cells (Santi et al. [@CR192_5]). For VLP vaccines, the foreign antigen is normally fused to the viral envelope protein or to a membrane domain, guiding and anchoring the antigen to the surface of the viral particle. The VLP presents the antigen to the immune system in its natural length and native structure. The particulate nature of the vaccine promotes immune recognition of the heterologous antigen (Bach et al. [@CR9_5]; Hunter et al. [@CR99_5]; Li et al. [@CR129_5]; Nikles et al. [@CR171_5]; Walpita et al. [@CR221_5]). Until today, there are different antigens tested for their capacity to induce a protective immunity or to break immunological tolerance. Thus far, no VLP-based vector vaccine has entered clinical testing phase.Fig. 5.4*Human and veterinary viral vaccine vectors*. Different viruses are developed as viral vector vaccines. Some are investigated in clinical trials directed against either pathogens such as viruses, bacteria, and parasites or other diseases (e.g., cancer, allergy)

A new vaccine approach against HIV was developed in the macaque AIDS model using pathogenic SIVmac239 as disease-inducing agent. For vaccination, rhesus cytomegalovirus (RhCMV), a replication competent and persistent but normally harmless virus, was equipped with a set of SIV antigens. This vaccine was shown to completely control SIV infection and spreading in some of the infected animals which was normally not achieved with the more common prime--boost strategies with highly immune activating but replication incompetent viral vectors. The continuous antigen delivery by the RhCMV/SIV vaccine in combination with the ability to stimulate an effector memory T-cell response was suggested as reason for this vaccination success (Hansen et al. [@CR89_5]). Such vector systems might provide a new way for the development of effective HIV vaccines.

Oncolytic Viruses {#Sec21_5}
-----------------

In the last century, clinical observations reported that cancer regression coincided with virus infections. However, tumor regression was mostly transient and incomplete (Kelly and Russell [@CR107_5]; Sinkovics and Horvath [@CR200_5]). At that time, there was no knowledge on virus infections, immune responses, and the correlate to tumor regression, and therefore, the use of oncolytic viruses today demands the investigation of those parameters. Reovirus, vaccinia, measles, adeno, herpes, vesicular stomatitis virus, as well as Newcastle disease virus, are the viruses mainly considered for therapies of cancer by oncolysis. The first approved oncolytic virus H101 has been approved in 2005 in China but not in Europe or the USA (Kirn [@CR112_5]). It is a ΔE1B adenovirus variant. For the improvement of safety, i.e., the tumor-specific infection and replication as well as efficacy, i.e., destruction of the tumor and eventually also metastases, it is essential to understand viral tropism and host restriction in addition to the influence of the molecular phenotype of the tumor. Techniques to specifically modify viruses for a rational design and the development of safe and efficient oncolytic viruses are already available. For instance, retargeting through modification of viral envelope proteins or their substitutions as well as activation or restriction of viral replications through specific viral gene deletions are necessary to generate safe and tumor-specific viruses. In addition, arming and shielding oncolytic viruses will improve oncolytic efficacy. Arming refers to equipping the virus with genes encoding prodrug-converting enzymes or immune stimulatory proteins to enhance antitumor activity. Shielding can be done chemically or biologically by using different viral serotypes to prevent neutralization by preexisting virus-specific antibodies (Cattaneo et al. [@CR28_5]).

Recent reports indicate synergistic effects between direct viral oncolysis and activation of specific antitumor immune responses. This suggests the inclusion of immunotherapeutic approaches into viral antitumor therapy (Boisgerault et al. [@CR18_5]). Among various immunomodulatory proteins that have been proposed, the most successfully employed immune-stimulating factor in advanced oncolytic viruses is the granulocyte-macrophage colony-stimulating factor (GMCSF). A second molecule is interferon-ß, although recombinant viruses harboring the corresponding gene have not entered clinical trials yet (Melcher et al. [@CR158_5]). Besides, proteases, glycosidases, and strategies that target angiogenesis are also tested with respect to their antitumor activity (Boisgerault et al. [@CR18_5]).Table.5.2Overview of the features of viral vectorsHuman adenovirus (HAdV)Modified vaccinia virusMeasles virusYellow feverCanarypox virusFamily*AdenoviridaePoxviridaeParamyxoviridaeFlaviviridaePoxviridae*Genus*MastadenovirusOrthopoxvirusMorbillivirusFlavivirusAvipoxvirus*SpeciesSix species (A--F)Vaccinia virusParamyxovirusesNatural forms: urban yellow fever, sylvatic yellow feverFor vaccines used: 17D yellow fever virus strainFowlpox virusSerotypes53 SerotypesGenome34--43 kb double-stranded DNA178 kb double-stranded DNASingle-stranded, negative-sense RNASingle-stranded, positive-sense RNADouble-stranded DNACellular receptorsCoxsackie adenovirus receptor, heparin-sensitive receptor, CD46, CD80, and CD86UnknownSLAM and CD46In discussion: GlycosaminoglycansInsert capacity\~7.5 kb25 kb6 kb

Animal Models {#Sec22_5}
=============

To study the safety and efficacy of a new vaccine candidate, preclinical evaluation in animals precedes in most cases testing in humans. Various mouse models are often used to establish first proof of concept for a new vaccine in vivo with regard to its safety and efficacy. Since pathogen--host interaction differs between mouse and human, careful selection of the pathogen for challenge experiments and the appropriate mouse strain (or an alternative animal model) is necessary in order to obtain relevant data.

For example, in the case of efficacy testing of poxvirus vaccines, the most common challenge model uses the lab-adapted VACV strain Western Reserve in mice. Even though special safety equipment is demanded for work with ectromelia virus, however, as the natural mouse pathogen causing mousepox, this virus resembles much more the course of disease progression of a variola virus in humans than the Western Reserve strain. To define the best route of challenge, virus administration is also important. Besides footpad inoculation, intranasal infection appears to mimic a more natural route of poxvirus infection. Thus, this virus--animal model represents an optimal small animal model to study MVA and orthopoxvirus immunogenicity and vaccine success (Paran et al. [@CR177_5]; Paran and Sutter [@CR176_5]). Other viruses, e.g., HIV, measles virus, and Ebola virus, cannot infect or replicate in mice due to strict host specificity. For such viruses, other target animals such as monkeys are needed. In the case of HIV, infection of macaques with the simian immunodeficiency virus (SIV) is still an important animal model for the understanding of HIV pathogenesis and the development of novel HIV vaccines. A natural SIV variant defective in the Nef gene function was found to induce protective immunity against an SIV challenge and thus can provide a valid tool to study the immune parameters that confer protection against the challenge virus (Daniel et al. [@CR48_5]). However, due to ethical concerns and high costs, low numbers of animals can be used in experimental settings. An alternative attempt is made to develop new mouse strains transgenic for human components. For example, a mouse transgenic for the human SLAM receptor enabled measles virus infection and replication in otherwise resistant mice (Ohno et al. [@CR173_5]). Additionally, immunogenic parameters that would also be representative for humans cannot always be found in animal models. Therefore, so-called humanized mice are developed which lack parts of their own immune system and thus can be reconstituted with human hematopoietic stem cells from which functional human immune cells can develop (Legrand et al. [@CR124_5]). Similarly, humanized mice have been successfully tested in infection experiments using *S. typhi*, a bacterial pathogen that is exclusively restricted to humans (Song et al. [@CR251_5]). Although the procedure to humanize mice is experimentally still very challenging, it is reasonable to expect that this system will be more and more introduced into testing of vaccines and therapeutics for intended human use.

Conclusion and Outlook {#Sec23_5}
======================

The use of LAV has made an indispensable contribution in the fight against infectious diseases. While initially undirected mutagenesis or extended passaging was employed to render the vaccine safe, today, modern molecular genetics allows the rational design of live microbes as a more efficient and safer vaccine or as vector systems for the delivery of heterologous prophylactic and therapeutic macromolecules. A number of bacterial, viral, and in some cases eukaryotic vector systems are considered as prospective carriers for protein, nucleic acid, or polysaccharide cargos. In addition to vaccination, live vectors offer new routes for the treatment of various disorders, such as cancer, gene deficiencies, allergies, or autoimmune diseases. However, the introduction of a new generation of recombinant live vector systems into medical practice is a long endeavor. In order to meet all requirements for approval, the safe, efficacious, and controlled use of such systems has to be carefully demonstrated in preclinics and the clinics. In addition, risks associated with genetically modified LAV, which might be released into the environment, have to be comprehensively assessed. The recent introduction of several recombinant bacterial and viral LAV into practice is a valuable proof of concept and will help to pave the roads for the development of such vaccines in the future.
